Editor's key points † This study determines compartmental pharmacokinetic parameters for nefopam during hypothermia. † The plasma concentration time course best fitted a two-compartment model using a population approach with inter-occasional variability. † No statistically significant covariates were found. † This model can be used to optimize nefopam administration by target-controlled infusion.
Among the potential pharmacological approaches to inducing hypothermic tolerance is nefopam. Nefopam is a nonopioid, non-steroidal analgesic with spinal and supraspinal sites of action that selectively reduces the shivering threshold (triggering core temperature) without impairing respiration or conciousness. 13 -19 It is a benzoxazocine compound, structurally related to orphenadrine and diphenhydramine, that inhibits the reuptake of serotonin, norepinephrine, and dopamine 20 in an amphetamine-like fashion. 18 Nefopam reduces the shivering threshold and can thus facilitate the induction of therapeutic hypothermia. 21 Although limited pharmacological data are available, 22 full compartmental models for nefopam during hypothermia were not readily available. Thus, the goal of this study was to determine compartmental pharmacokinetic (PK) parameters for nefopam during hypothermia.
evaluated eight young, healthy volunteers who took no medications and denied alcohol or drug abuse. After nefopam administration, lactated Ringer's solution at 48C was infused to provoke shivering which was the primary outcome of the primary thermoregulatory protocol. The maximum reduction in core temperature was .1.58C. Throughout the study, volunteers rested supine. A 14 G catheter was inserted into one antecubital vein for fluid administration and a 16 G catheter into the other for drug administration. Blood samples were drawn from a 20 G catheter inserted into a radial artery on the upper extremity. On two different occasions, with a washout time of more than 48 h, nefopam (Acupan, Laboratoires Biocodex, Montrouge, France; IUPAC name: 5-methyl-1-phenyl-1,3,4, 6-tetrahydro-2,5-benzoxazocine) was administered as a continuous i.v. infusion at two randomly assigned concentrations (0.5 mg ml 21 or 1.0 mg ml 21 ) according to one of the schemes displayed in the Appendix (volunteers 1-4, scheme A; volunteers 5-8, scheme B). Arterial blood was sampled for PK analysis according to the following scheme: a blank sample; during nefopam administration at minutes 2, 4, 6, 8, 10, 12, 15, 20, 30, 45 , and 60, and immediately before stopping the nefopam infusion; if applicable, depending on the pharmacodynamic study part, additionally at minutes 120, 150, and 180. The number of samples during nefopam administration depended on the duration of the thermoregulatory study. After stopping the nefopam infusion, samples were gathered at minutes 2, 4, 6, 10, 15, 20, 30, 45, 60, 90, 120, 180, 275, 360, 450, 540, and 630.
Plasma was extracted in a refrigerated centrifuge and stored at 2208C until assayed. Before extraction, plasma samples for nefopam analysis were allowed to thaw at room temperature and vortexed, then centrifuged at 2000 rpm for 5 min. To 0.5 ml of plasma, 0.5 ml of deionized water, internal standard (IS, imipramine hydrochloride, ICN Biomedicals Inc., OH, USA), and 30 ml of orthophosphoric acid were added and vortexed. The samples were loaded (about 0.5 ml min 21 ) on 96-well solid phase extraction plates with 2 ml capacity and 30 mg extraction bed (OASIS, MCX, Waters Corporation, Milford, PA, USA). The cartridges were rinsed with 2 ml of 0.1 M hydrochloric acid, 2 ml of methanol, and then dried under vacuum for at least 5 min. The extracts were then eluted from the cartridge with 2.5 ml of freshly prepared methanol -ammonium hydroxide 25% (95:5; vol:vol), by gravity flow. The eluate was evaporated to dryness under a nitrogen stream in a water bath at about 408C. The residues were redissolved in 30 ml methanolbutylacetate (4:1; vol:vol), briefly vortexed, and loaded into auto-sampler vials with inserts. Samples were analysed by GC -MSD (Agilent Technologies, USA, Model 6890 with a 5972A mass selective detector and automatic injector). Aliquots of 1 ml were injected in a splitless mode onto a Varian FactorFour VF-Xms, 12 m, 0.2 mm ID capillary column with a 0.33 mm film. The helium flow rate was 0.8 ml min 21 . Operating temperatures of the GC were: injector 2508C, MSD transfer line 2808C, oven 1408C for 0.2 min rising (258C min 21 ) to 2808C, hold 1 min. The MSD was operated in the electron impact mode (70 eV) with selected ion monitoring (SIM) with a dwell time of 100 ms each. SIM ions for quantitation were m/z 225 and 235 for nefopam and IS, respectively. The data were processed with proprietary mass spectrometer control software (HP G1701AA). All calibration curves had correlation coefficients ≥0.99. The coefficient of variation (CV) of intraday reproducibility (n¼10) for nefopam at 301, 103, and 10.3 ng ml 21 blood content was 2.0%, 2.2%, and 3.7%, respectively. CV of interday reproducibility at the same concentrations (n¼6) was 4.5%, 5.3%, and 7.4%, respectively. The mean recovery of nefopam (n¼15) at concentrations 10-300 ng ml 21 was 92.5% (range 87-104%). The limit of quantification at a signal-to-noise ratio of 10:1 was 4.4 ng ml 21 . The limit of detection at a signal-to-noise ratio of 3:1 was 1.3 ng ml 21 .
One-, two-, and three-compartment mammillary models were fitted to the nefopam plasma concentration data and compared using the Akaike information criterion. 24 The models were parameterized in terms of volumes of distribution, elimination, and distributional clearance (Cl el , Cl dist ). Pooled data were initially used, which means that each data set was handled as if it was a single subject. In a second step, we specified that the same subject participated on two different occasions. Investigations were done with a non-population and a population approach. In a third step, intra-occasional variability (IOV) was taken into consideration.
Inter-individual variability (IIV) was characterized by an exponential model: u (n,i) ¼u (n,m) ×e h(n,i) , where u (n,i) refers to the individual value of the respective PK parameter, u (n,m) the population mean of the parameter, and h(n,i) denotes the ln-difference between u (n,i) and u (n,m) . IIV is the square root of the variances of the ETAs and is expressed as percentage value. The IOV, the variability within one individual between study occasions, had the same exponential structure: u (n,iq) ¼u (n,m) ×e h(n,i)+k(n,iq) , where q denotes the occasion and k(n,iq) the additional random effect differing from the typical individual value. h(n,i) and k(n,iq) are assumed to vary randomly between individuals with a mean of zero and a diagonal variance-covariance matrix v 2 and p 2 , respectively.
Residual variability denotes the discrepancy between the observed and the model-predicted concentrations already containing the IIV and IOV. A multiplicative error model was chosen: c obs ¼c exp (1+e), where c obs refers to the observed concentration and c exp to the concentration predicted based on dose, time, and the individual PK parameters. e was assumed to be normally distributed with a mean of zero and variance s 2 .
Covariates were age, weight, height, BMI, lean body mass (LBM), and body surface area (BSA). The parameters were plotted against these covariates for visual inspection. Covariates were added one by one and kept in the model if they improved the goodness of fit (forward inclusion, backward deletion), judged by the likelihood ratio criterion (P≤0.01).
We tested for model misspecification by plotting the ratio of the measured and the predicted nefopam plasma concentrations against observation time. Additionally, the predictive performance of the final model was determined applying prediction error (PE) analysis. 25 
PE = 100(measured concentration−predicted concentration) predicted concentration
The median PE (MDPE) indicates the bias of the predicted concentration to the measured one and the absolute value of PE called the median absolute PE (MDAPE) characterizing the precision of the prediction. The model is most accurate the closer the value of MDPE and MDAPE is to 0. Typical accepted values during target-controlled infusion (TCI) are ranging between 220% and 20% for the MDPE and ,30% for the MDAPE. 26 For all calculations, NONMEM version VII with the first-order conditional estimation for all model fits and empirical Bayesian estimation of the individual parameters was used. 27 The bootstrap was performed using
Perl speaks NONMEM (Version 3.2.12; http://psn.sourceforge. net), with a total of 2000 bootstrap samples being generated by repeated random sampling from the original data set preserving the two occasions per individual. Boundaries for the elimination clearance were 0 and 100 litre min 21 .
Context-sensitive decrement times for the plasma concentration were calculated using RECOV.C targeting times to 80%, 50%, and 20% decrements.
Results
If not otherwise indicated, the values are presented as mean (SD) (min-max): age 28 (7) (21-39) yr, weight 78 (9) (63-92) kg, and height 179 (4.7) (170 -185) cm. Two of the eight volunteers were female. Five hundred blood samples (249 from scheme A and 251 from scheme B) were available for PK calculations, including the blank samples obtained before drug administration. A total of 3.04 (0.78) litre lactated Ringer's solution at 48C were administered on the low-concentration day (0.5 mg ml 21 nefopam) and a total of 3.43 (1.01) litre were used on the high-concentration day (1.0 mg ml 21 nefopam).
Raw plots of the measured nefopam plasma concentration were constructed for infusion schemes A and B, and showed a typical initial peak followed by a decrease in the nefopam plasma concentration reaching a plateau until maintenance application was terminated. Subsequently, plasma concentrations decreased (Fig. 1) .
The plasma concentration time course best fitted a twocompartment model using a population approach with interoccasional variability (Table 1) . No statistically significant correlation between model parameters and age, weight, height, BMI, LBM, and BSA was found. The influence of sex was not evaluated.
A goodness-of-fit plot for the two-compartment model shows that the Bayesian prediction for each volunteer matched the observations (measured plasma concentrations) well over the entire concentration range (Fig. 2) . The PK parameters of nefopam are shown in Table 2 . The central compartment V 1 was 24.3 litre and clearly larger than the blood volume undergoing a quick distribution (t 1/2a ¼4.5 min) into an even larger compartment V 2 with 183.3 litre being eliminated from plasma with a terminal plasma elimination half-life of 5 h. IIV ranged from 15.7 (V 2 ) to 39.1 (V 1 ) %CV as given in Table 2 . The IOV was estimated to be between 7%CV (Cl el ) and 16%CV (V 1 ).
Plotting the relative residuals of the population and Bayesian prediction against time and concentrations, respectively, showed that the model misspecifications were well controlled, the Bayesian approach delivering more accurate predictions (Fig. 3) . The MDPE (10th; 90th percentile) for the final model was 26.15 (225; +16)% and the MDAPE was 16.63 (10; 29)%. Table 2 . Nefopam will be used for the purpose of inducing tolerance to mild hypothermia. The main methods of inducing and maintaining mild hypothermia are i.v. application of cold fluids, applying ice or chemical packs, wrapping in mattresses or other special cooling gants, cold forced air, and endovascular cooling. Often a combination is applied, prioritizing cold fluid application initially. One study used 30 ml kg 21 lactated Ringer's solution at 48C infused over 30 min via a peripheral i.v. access. 32 The median temperature decreased after the bolus was 1.68C. Another study used ice-cold saline solution, cold packs, and mattresses. 33 Core cooling in our study resulted from infusion of an average of 3.0-3.5 litre cold lactated Ringer's solution. The amount of volume administered in our study is slightly greater than the one based on the recommendation by the abovementioned studies [2.3 (0.3) litre calculated for our study population] for induction of therapeutic hypothermia but reflects a whole study cycle (induction+maintenance) and -axis) , stopping the infusion would take the time indicated on the y-axis to reach one of the decrement portions. Once steady state is reached, the times for the 80%, 50%, and 20% decrements are 38, 248, and 660 min. deals with non-anaesthetized volunteers compared with anaesthetized patients. Therefore, the gathered data and derived kinetics mirror clinical handling of the targeted field of nefopam use to a great extent. This is a potential benefit because data obtained in normothermic patients would need to be extrapolated to hypothermic conditions that we already incorporated in the study. On top of the thermal influence on the kinetic parameters, slight differences in the mode of administration, sampling, and calculating parameters need to be taken into account. In the normothermic study, people received a single dose of 20 mg only, administered over 30 min, 31 whereas the hypothermic study administered up to 64 mg continuously over a period up to 3 h, covering loading and maintenance as well. The normothermic study lacks a maintenance infusion and did not reach a steady state. Therefore, values of the normothermic study are more prone to calculation errors, since kinetic parameters needed to be extrapolated by the software rather than being based on measured concentrations during a real maintenance period. Both thermal manipulations and volume application in our study reflect current practice in clinical use of mild hypothermia, one field of nefopam assignment. In detail: during the period of mild hypothermia and shivering, the measured nefopam plasma showed a peak in the concentration curves (Fig. 1) . It is unclear if this effect could be attributed to periods of increased shivering activity. Before thermal manipulations took place, a stable nefopam plasma concentration was established; after terminating cooling and stopping the nefopam maintenance infusion, a regular decrease in the nefopam plasma concentration was observed (Fig. 1) . The determined value for the terminal plasma elimination half-life time of nefopam found in our investigation is in accordance with the one Aymard and colleagues 28 found with a different method and without thermal manipulations. Nevertheless, the model we determined describes the values during all phases, including thermal manipulations. We used serial samples in each volunteer, administering nefopam with two different concentrations (one concentration per occasion) on two different occasions. The minimum objective function values of the model building process are shown in Table 1 . As expected, treating two different infusion regimes in one volunteer as two independent individuals delivers slightly better results. Nevertheless, the correct declaration of two different dosing regimes in the same subject on different occasions was used for the presented data and also distinguishing between a population and a non-population approach. Furthermore, introducing IOV in the model further lowered the minimum value of the objective function from 3045 to 2858 and proved essential to avoid biased population parameter estimates. 34 During bootstrapping, 525 runs, equalling 26%, were skipped with estimates near a boundary. In all cases, they were estimates of the elimination clearance. From a statistical point of view, the skipped runs could bias the result. The mean of the remaining runs is close to 0, but the SD is only about 0.6. This could lead to an underestimation of the CIs. The value for the elimination clearance derived during model building is in accordance with values of other publications determining it with different methods. Furthermore, the standard errors in modelling during the covariance step show comparable results with bootstrapping (values not displayed). Since we found similar results to other groups for the elimination clearance and results in modelling and bootstrapping are comparable, we hold the compartment model established for a valid tool. It is no secret that there has been a big controversial discussion in the community for years, if parameters reaching a boundary should be discarded from the bootstrap distribution; not only we believe it is the best way to do so. Values beyond the used range could cause numerical problems leading to estimated values outside a reasonable physiological range.
The initial peaks seen in Figure 1 resulted from partial overdosing, since the necessary amount of drug to be infused was derived by estimation from available data. Now, with the determined compartmental data set, such overdosing could be avoided. With the compartmental data set, the initial loading could be calculated to saturate the central compartment without causing an overshoot (and possible side-effects), replenishing the amount of drug being distributed to peripheral compartments, or being eliminated. By implementing this compartmental PK data set (Table 2 ) into infusion pumps, the process could be automated. After choosing a desired nefopam plasma concentration, the infusion pump will establish and maintain this concentration relieving work load on medical personnel.
In Figure 2 , we plotted measured vs predicted plasma concentrations [predictions based on individual doses and typical parameter values (¼population predictions), individual doses and individual parameter values (¼Bayesian predictions)]. The Bayesian predictions match the observations well over the entire concentration range. The fact that several measured concentrations .200 ng ml 21 deviate profoundly from the population predictions and that these data points were observed during the initial infusion time becomes obvious when cross-checking Figure 2 with Figure 1 . It is well known that compartment models (assuming instantaneous mixing) are not adequate for this initial phase. A second option to explain such a bias for higher concentrations would be non-linearity in such a way that the clearance is not constant over the complete concentration range but limited, for example, by enzyme capacity. Only during the initial phase, loading concentrations .200 ng ml 21 were measured. Furthermore, assessing the inter-individual variability of parameters determining the drug concentrations in this phase before steady state (Table 2) , both the central volume of distribution and the distribution clearance display the largest IIV (CV 39% and 31%, respectively). After termination of the infusion, the decrease in plasma concentrations is predominantly related to the Cl el , which displays only modest IIV (CV 23%). This fact is supported by the MDPE of 26.15% showing a slight overestimation of the model compared with the measured values. Thus, we attribute the deviations of the population predictions from the measured values at concentrations .200 ng ml 21 to the known effect that compartment models are not completely adequate for the initial phase. Another limitation of the study is the small age range (21 -39 yr) of people participating in the study. Furthermore, the effects (if any) of gender could not be analysed, only two women participated. Thus, nefopam kinetics for children, the elderly, and women remain to be investigated. Because the spread of biometric parameters (age, weight, height, sex) in the study population was insufficient, we cannot conclude that nefopam dosing is independent of weight, although this is the current situation in clinical use.
To achieve and maintain a nefopam plasma concentration of 100 ng ml 21 , scheme B with a nefopam concentration of 1 mg ml 21 could be used. That scheme incorporates a ramping to minimize the risk of side-effects such as nausea and vomiting or dizziness. Nevertheless, adjusting the infusion rate every few minutes is uncomfortable and timeconsuming. Therefore, the use of a target-controlled automated pump using the determined kinetic data set is recommended. Furthermore, it allows us to establish various plasma concentrations, as desired (with the variability underlying a TCI system).
In conclusion, this is the first compartmental pharmokinetics of nefopam during hypothermia. A two-compartment model with IOV reliably characterizes nefopam kinetics and enables predictions of nefopam plasma concentrations at any time point and could be used to establish and maintain nefopam plasma concentrations, even automated by infusion pumps. 
